WHO ICTRP trial
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone…
EUCTR2004-002832-24-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2004-002832-24-DE |
|---|---|
| Public title | Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or endocrine treatment - ProBONE II |
| Scientific title | Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or endocrine treatment - ProBONE II |
| Primary sponsor | Novartis Pharma GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Hormonreceptor positive breast cancer in premenopausal women |
| Interventions | Product Name: Zometa 4mg/5ml Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Zoledronic acid Current Sponsor code: CGP42446 Concentration unit: mg milligram(s) Concentration type: equal Concentration number… |
| Registration date | Nov 29, 2005 |
| Secondary IDs | CZOL446GDE21 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: